Pfizer
Pfizer Inc. (NYSE: PFE) is a research-based global biopharmaceutical company headquartered in New York and operates through its website at www.pfizer.com. The company applies science and global resources to discover, develop, manufacture, market, sell and distribute biopharmaceutical products worldwide, focusing on… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Pfizer does
In the company’s own words
Pfizer Inc. (NYSE: PFE) is a research-based global biopharmaceutical company headquartered in New York and operates through its website at www.pfizer.com. The company applies science and global resources to discover, develop, manufacture, market, sell and distribute biopharmaceutical products worldwide, focusing on extending and significantly improving patients' lives through medicines and vaccines that address major diseases.
The company operates through three primary divisions within its Biopharma reportable segment, which represents the only reportable segment. The Pfizer U.S. Commercial Division commercializes the entire product portfolio in the United States. The Pfizer International Commercial Division handles commercialization across all international markets. The Global Hospital and Biosimilars organization manages off-patent branded and generic sterile injectables and biosimilars. Additionally, Pfizer operates PC1, a contract development and manufacturing organization supplying specialty active pharmaceutical ingredients, and Pfizer Ignite, which provides R&D services to biotech companies, though the company decided to discontinue Ignite in 2025.
Pfizer's product portfolio spans four primary therapeutic areas: oncology, internal medicine including cardiometabolic and weight management treatments, vaccines for infectious diseases, and inflammation and immunology. Major brands include Comirnaty (COVID-19 vaccine developed with BioNTech), Paxlovid (COVID-19 treatment), Eliquis (anticoagulant), Prevnar family (pneumococcal vaccines), Xtandi (prostate cancer treatment), Ibrance (breast cancer treatment), and the Vyndaqel family (amyloidosis treatment). The company also maintains collaboration and co-promotion agreements with partners including BioNTech, Bristol-Myers Squibb, and Astellas for various products.
The company's R&D operations are managed through a single global organization focused on discovering and developing highly differentiated medicines and vaccines. As of early 2026, Pfizer maintained numerous projects in various development stages across its therapeutic focus areas. The company pursues business development through acquisitions, in-licensing agreements, and strategic partnerships to enhance its pipeline and capabilities. Recent significant transactions include the November 2025 acquisition of Metsera and the December 2023 acquisition of Seagen, along with in-licensing agreements with YaoPharma and 3SBio in obesity, cardiometabolic diseases, and oncology.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- NEW YORK, NY
- Fiscal year end
- December
- CIK
- 78003
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Pfizer — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Pfizer · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Pfizer’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Pfizer’s bonds, as funds hold them
Funds report holding 38 issues of Pfizer’s debt, $6.49B at market value — what funds hold, not the company’s total debt. Weighted-average coupon 4.47%, maturing 2026 to 2065.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Pfizer and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Pfizer's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Pfizer's last four quarterly filings that the numbers alone won't show?”